Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $127.6 million.

  • Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) rose 267.15% to $127.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.6 million, marking a year-over-year increase of 267.15%. This contributed to the annual value of $121.0 million for FY2024, which is 7452.82% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) stood at $127.6 million, which was up 267.15% from $127.0 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) ranged from a high of $127.6 million in Q3 2025 and a low of $47.3 million during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $61.4 million (2023), whereas its average is $80.3 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 10137.34% in 2024, then soared by 267.15% in 2025.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) stood at $49.4 million in 2021, then rose by 11.39% to $55.0 million in 2022, then grew by 25.94% to $69.3 million in 2023, then skyrocketed by 74.53% to $121.0 million in 2024, then rose by 5.51% to $127.6 million in 2025.
  • Its last three reported values are $127.6 million in Q3 2025, $127.0 million for Q2 2025, and $126.0 million during Q1 2025.